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2002) were supported by adequate reliability data (coefﬁcient
alpha > 0.7) and multiple validation studies. Overall, when data
was available, in a majority of the cases, measures met study
standards. CONCLUSION: Evaluation of patient satisfaction
with pharmacist cognitive services is critical to optimizing
patient care in a clinical or community setting. To accomplish
this, precise and valid measures are vital; however, no one instru-
ment met all criteria. Lack of reported data warrants further
research documenting an instrument’s psychometric properties,
ease of administration, and ability to capture the multidimen-
sional nature of patient satisfaction.
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OBJECTIVES: The US Valuation of the EQ-5D Health States
was conducted to predict US societal preferences for the 243
health states described by the EQ-5D. The model used to gener-
ate these predictions (i.e., the D1 model) addressed a number of
important conceptual and statistical issues. However, it has been
criticized for being too complex and for failing to account for
the non-normal distribution of health state preferences. Further-
more, the model’s developers have been faulted for applying an
arbitrary transformation to the values for worse-than-death
health states prior to estimation. This paper describes the devel-
opment of an improved model for predicting US preferences for
EQ-5D health states. METHODS: Model parameters were esti-
mated using a probability-weighted least absolute deviations esti-
mator. Variance estimation proceeded using a replication-based
jackknife method. The resulting model predictions were con-
trasted with those of the D1 model. The ﬁt of a median model
for data collected in the Measurement and Valuation of Health
study was also studied. RESULTS: When applying no transfor-
mation to the values for states worse than death, the best-ﬁtting
model included only ﬁxed effects for moderate or severe prob-
lems in each of the 5 EQ-5D dimensions and excluded a con-
stant. This speciﬁcation yielded a squared rank correlation
between observed and predicted values of 0.363, a median
absolute error of 0.025, and a rank correlation between median
observed and predicted values of 0.991. The predicted median
preferences ranged from 1.00 for full health to −0.80 for the
worst possible health state. CONCLUSION: The application of
a linear model to the US valuation data cannot be justiﬁed given
the non-normal distribution of health state preferences. A
median model of preferences is superior to other available spec-
iﬁcations. In applications requiring US societal preferences, it is
suggested that the predictions of the model discussed here be
used instead of those of the D1 model.
PMC26
EFFECT OF CHRONIC DISEASES ON HEALTH 
SERVICES UTILIZATION
Chen T1, Li L1, Du Y1, Lei J2
1Zhejiang University, Hangzhou, Zhejiang, China, 2University of
Goettingen, Goettingen, Lower Saxony, Germany
OBJECTIVES: Little research concerning to the effect of co-
morbidity on Health Service Utilization was conducted in ﬁeld
of General Practice. We aim to explore the effect of common
chronic diseases on the Health Service Utilization  G
METHODS: Cross-sectional design was conducted. 750 Sample
of patients was obtained via three stages of cluster sampling.
Each patient was asked whether or not he or she contracted fol-
lowing eight common chronic diseases diagnosed by doctor, i.e.,
hypertension, diabetes, heart attack of any category, apoplexy,
asthma or other respiratory disease (COPD), chronic arthritis,
mental disease and other disease lasting over four weeks. Our
research focuses on the relation between common chronic dis-
eases and Health Service Utilization (monthly consultation rate,
annual consultation rate and annual hospitalization rate).
RESULTS: Our research has shown that Health Service Utiliza-
tion of each chronic disease is all higher than reference group.
The overall number of chronic diseases has the linear relation
with annual consultation rate, monthly consultation rate and
annual hospitalization rate separately. Meanwhile, increasing
one type of chronic disease leads to adding additional 8.3 annual
consultation rat; the OR value of annual hospitalization rate is
1.786 which hints that increase one type of chronic diseases will
induce more 78.6% relative risk of possible hospitalization rate.
Furthermore, the other seven types of chronic diseases, except
for apoplexy, have a positive linear relation with annual consul-
tation rate; diabetes, cardiopathy and apoplexy have respectively
positive linear relation with annual hospitalization rate. CON-
CLUSION: Our systematical approach addressed the scarcity
that most researches in China only focus on single disease, espe-
cially in the ﬁeld of General Practice Research. Our research sup-
ports the assumption that common chronic diseases can be taken
as the predicting factor for risk adjustment model and can
predict health services utilization.
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OBJECTIVES: Up to date in mainland China, no data has been
shown the relationship between health-related quality of life
(HRQOL) and health services utilization. This study is aim to
conﬁrm the hypothesis that the scale-score of the SF-36 is in
linear relationship with Health Services Utilization, and to quan-
tify its linear relationship after the conﬁrmation of above hypoth-
esis. METHODS: Cross-sectional design was conducted. Sample
was obtained via three stages of cluster sampling. We use both
electronic version (based on QL-Recorder) and paper version of
SF-36. Data process was conducted by the structured multiphase
regression model. RESULTS: Firstly, in terms of monthly con-
sultation rate, the scale-score of the SF-36 separately intercepted
5.1% contribution. Secondly, with respect to annual consulta-
tion rate, the scale-score of the SF-36 solely explained 2.7% con-
tribution. Thirdly, referring to annual hospitalization rate, the
scale-score of the SF-36 explained 4.7%. Besides, our research
induces that there was gender difference of the scale-score of the
SF-36 on Health Service Utilization, namely, the female are
higher than the male. CONCLUSION: Our research proved, for
the ﬁrst time in Mainland China, that the hypothesis on linear
relation between the scale-score of the SF-36 and Health Service
Utility. We further calculated in quantiﬁcation, the separate con-
tribution rate of the scale-score of the SF-36 to Health Service
Utilization.
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OBJECTIVES: To determine the proportion of published cost-
minimization analyses (CMAs) that provided appropriate evi-
dence of equivalence between drug comparators. METHODS:
Medline, Embase, and International Pharmaceutical Abstracts
(from inception to December 2006) were searched using the
words “cost” and “minimization”. Included articles were those
that: claimed to be a CMA, compared costs between drugs,
reported original research, and were available as full-text
(abstracts/reviews/letters were not accepted). Data extraction
was performed by two independent reviewers and included: evi-
dence of equivalence, journal type, publication date, and class of
drug. To determine adequacy of evidence of equivalence, each
article was assessed for source of data as well as strength of effec-
tiveness between comparators, and categorized as: “adequate”,
“questionable”, and “inadequate”. All differences in raters’ deci-
sions were resolved through consensus. RESULTS: A total of 67
articles were assessed for evidence of equivalence. Of those, the
majority were from the US/Canada, followed by Europe. Only
one article was from outside these regions (Australia). CMAs
were most published in general medicine journals and in the ﬁeld
of cardiovascular drugs. Of the total accepted studies, 9 (13.4%)
were judged “adequate”, 21 studies (31.3%) were categorized as
“questionable”, and 37 (55.2%) studies had “inadequate” evi-
dence of equivalence of comparators. The majority of studies
failed to prove their comparators’ equivalence because the evi-
dence in the literature supported different outcome results,
because some of these studies simply assumed equivalence, or did
not provide any evidence at all. No correlation was found
between studies that provided “adequate” or “inadequate”
equivalence and year of publication. CONCLUSION: The
majority of studies failed to provide adequate evidence of the
suitability of CMA as an analytic technique. Guidelines should
be developed that explicitly specify criteria for the performance
of a CMA in future studies.
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OBJECTIVES: The incremental cost-effectiveness ratio (ICER) 
is commonly calculated by health-economic researchers as a
method to communicate the relative incremental value among
treatments. It is intended as evidence to determine whether a
drug is a good value. However, as a single number presented as
a value in a local currency it is poorly understood by the average
health care decision maker(s). The objective of this project was
to re-examine the ICER value and design an economic calcula-
tion that would be more readily understood and more easily
interpretable by the customers of health economic information,
the health care decision makers. METHODS: The components
of the ICER were evaluated and rearranged in various possible
calculations to yield a value that was comparable across differ-
ent treatments utilizing the available cost (price) and effec-
tiveness components of medical treatments. RESULTS: The
incremental effectiveness per incremental cost ratio (IECR) or
“incremental value” is proposed. The incremental difference in
effectiveness is expressed as a ratio to the incremental difference
in cost, with all factors expressed in percentages. We compared
the traditional ICER to the proposed IECR. If a new treatment
had an IECR value of 100% it would be considered neutral. If
the IECR was less than 100% it could be considered needing
alternative value, and any value greater than 100% would gen-
erally be considered positive value. Examples: Drug-A : Drug-B
Cost $100 : $160. Effectiveness 50% : 80%. ICER : IECR $200 :
100% = EVEN. Cost $100 : $140. Effectiveness 50% : 80%
ICER : IECR $133 150% = GOOD. Cost $100 : $180. Effective-
ness 50% : 80%. ICER : IECR $267 : 75% = POOR. CONCLU-
SION: The results of the IECR calculation are easily
interpretable and produce a value that is simple to compare
across treatments. The IECR removes The oretical value of the
ICER, which is difﬁcult for decision makers to interpret, and
replaces it with a value that has an interpretable reference range.
PMC30
GUIDELINES FOR BUDGET IMPACT ANALYSIS IN CANADA
Marshall D1, Douglas PR1, Drummond M2, MacLeod S3,
Torrance GW1, Manti O4, Cheruvu L4
1i3 Innovus, Burlington, ON, Canada, 2University of York,York,
Heslington, UK, 3British Columbia Child & Family Research Institute,
Vancouver, BC, Canada, 4Patented Medicine Prices Review Board,
Ottawa, ON, Canada
OBJECTIVES: Budget Impact Analysis (BIA) addresses the ques-
tion of whether a new drug is affordable by the health care
system in which it is being introduced. In Canada, committees
and managers of each public drug plan make reimbursement
decisions regarding new drugs. Most drug plan managers now
require economic data, including a BIA, as part of the formal
decision process on the pricing and reimbursement of drugs.
There is currently no standardized method of performing and
presenting BIAs for submission. METHODS: A survey of repre-
sentatives across Canada and a review of 35 previously submit-
ted BIAs were conducted to assess existing needs for BIA
guidelines. Based on these ﬁndings, previously published guide-
lines (ISPOR) and input from the project’s Steering Committee,
BIA guidelines were developed to provide detailed instruction on
how BIAs should be performed. An interactive budget impact
model template was designed to facilitate BIA model develop-
ment. RESULTS: Five key problem areas were identiﬁed for
improvement in BIA models: Lack of transparency, inaccurate or
misapplied assumptions, generalized analysis non-speciﬁc or
inaccurate to jurisdiction and/or plan, inappropriate choice of
comparators; and overall quality. The guidelines and accompa-
nying template address these problems and cover model design,
analytic perspective, time horizon, target population, costing,
scenarios to be compared, uncertainty analysis, discounting and
validation methods that should be used when preparing a BIA
as well as provide detailed guidance on data inputs and data
sources. CONCLUSION: The BIA guidelines and accompanying
template address the requirements of each of the participating
drug plans in Canada. Both have been endorsed by the National
Prescription Drug Utilization Information System (NPDUIS)
Steering Committee and the PMPRB for the standardization of
BIA submissions. The intended audience includes those who
develop, submit or use BIA models, and drug plan managers who
evaluate BIA submissions.
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OBJECTIVES: Any economic evaluation of a health care inter-
vention is only as good as the effectiveness data it is built upon
(Drummond 1997). Despite this knowledge, the quality of infor-
mation on clinical effectiveness is still poor. METHODS: The
main reason is that most data, at least on medicinal drugs, is tai-
lored towards obtaining a market authorisation. Competent
authorities, in the European Union, the United States and
